There are now three approved drugs that target PD-1 either directly or indirectly, and more are under development.While these drugs all seek to inhibit PD-1’s immune suppressive activity, they are quite different in the ways that companion diagnostic tests play...
We are soon going to release a report describing trends in the development and use of companion diagnostic biomarkers, and a key part of preparing this report was breaking down companion diagnostic biomarkers into relevant groups. A very clear initial division is...
In a recent post we introduced the idea of the Personalized Medicine Scorecard, and to further develop these rankings we promised to analyze the pipelines of each company in the Scorecard. Download the Scorecard Whitepaper here. As a first step in this effort, this...
The challenges faced by oncologists in using biomarker-based tests were underlined in a recent article by Dr. Marcus Neubauer in OncLive. In recent posts in this blog I have focused on the challenges of interpreting genomic data, but Dr. Neubauer emphasizes two...
A new method for prognosing ovarian cancer was recently described by researchers from the University of Utah. While I am particularly interested in precision medicine developments for ovarian cancer, as it is an especially under-served disease, I am not...
